AD biomarker discovery in CSF and in alternative matrices

Giulia Sancesario, Sergio Bernardini

Research output: Contribution to journalReview article

Abstract

Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.

Original languageEnglish
JournalClinical Biochemistry
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Cerebrospinal fluid
Biomarkers
Cerebrospinal Fluid
Alzheimer Disease
Cerebrospinal Fluid Proteins
tau Proteins
Tears
Saliva
Amyloid
Brain
Mirrors
Blood
Clinical Trials
Urine
Guidelines
Technology
Molecules
Fluids
Research

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

AD biomarker discovery in CSF and in alternative matrices. / Sancesario, Giulia; Bernardini, Sergio.

In: Clinical Biochemistry, 01.01.2019.

Research output: Contribution to journalReview article

Sancesario, Giulia ; Bernardini, Sergio. / AD biomarker discovery in CSF and in alternative matrices. In: Clinical Biochemistry. 2019.
@article{80a2cf8b20844be29e87a76288e5387c,
title = "AD biomarker discovery in CSF and in alternative matrices",
abstract = "Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.",
author = "Giulia Sancesario and Sergio Bernardini",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2019.08.008",
language = "English",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - AD biomarker discovery in CSF and in alternative matrices

AU - Sancesario, Giulia

AU - Bernardini, Sergio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.

AB - Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.

UR - http://www.scopus.com/inward/record.url?scp=85071383338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071383338&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2019.08.008

DO - 10.1016/j.clinbiochem.2019.08.008

M3 - Review article

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -